3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Melanoma
11
Triple Negative Breast Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Neoplasms
7
Head and Neck Neoplasms
7
Multiple Myeloma
6
Carcinoma, Transitional Cell
6
Carcinoma, Renal Cell
6
Pancreatic Neoplasms
5
Lung Neoplasms
4
Recurrence
3
Prostatic Neoplasms
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Sarcoma
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Kidney Neoplasms
2
Inflammatory Breast Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Urothelial Cancer
1
Thyroid Neoplasms
1
Subcutaneous panniculitis-like T-cell lymphoma
1
Spinocerebellar Degenerations
1
Interventions
tucatinib
1
pembrolizumab
1
XENP 1595
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Central Nervous System Diseases
×
pembrolizumab
×
Clear all
NCT04512261
2022-07-01
TOPAZ
Cedars-Sinai Medical Center
Phase 1/2
Withdrawn